SCHEDULE 13D/A: Pyxis Oncology CEO Lara Sullivan Boosts Stake with New Stock Option Grant

Pyxis Oncology, Inc.'s President, CEO, and Chief Medical Officer, Lara Sullivan, has increased her beneficial ownership to 11.21% of the company's common stock following a new stock option grant.

Summary

• Lara Sullivan, President, CEO, and Chief Medical Officer of Pyxis Oncology, Inc., beneficially owns 7,543,007 shares of the company's common stock, representing approximately 11.21% of the total outstanding shares.
• This beneficial ownership includes 5,139,125 shares obtainable upon exercise of options and 537,335 shares obtainable upon vesting of Restricted Stock Units (RSUs), both subject to continued employment.
• On March 31, 2025, Ms. Sullivan was granted a new stock option to purchase 918,308 shares at an exercise price of $0.98 per share.
• The newly granted stock options vest over a four-year period, with 25% vesting on the first anniversary of the grant date and the remaining 75% vesting in 36 equal monthly installments thereafter, contingent on her continued employment.
• The beneficial ownership percentage is calculated based on 61,590,415 shares outstanding as of March 17, 2025, plus the exercisable options and vesting RSUs held by Ms. Sullivan.

Sentiment

Score: 7

Explanation: The filing indicates stability in leadership and a standard executive compensation practice, aligning management's interests with long-term company performance. The increase in beneficial ownership by the CEO is generally viewed positively as a sign of confidence.

Positives

• The grant of stock options aligns management's interests with shareholder value creation.
• Lara Sullivan's increased beneficial ownership demonstrates her commitment to the company's long-term success.
• The vesting schedule incentivizes Ms. Sullivan's continued employment and dedication to Pyxis Oncology.

Negatives

• The stock options are subject to a four-year vesting period, meaning the full benefit is not immediately realized.
• The value of the options is dependent on the future stock price exceeding the exercise price of $0.98 per share.

Risks

• The vesting of stock options and RSUs is contingent upon Lara Sullivan's continued employment, posing a risk if her employment ceases.
• The value of the stock options is subject to market fluctuations and the company's future performance.

Future Outlook

The vesting schedule for the newly granted stock options over a four-year period, contingent on continued employment, indicates an expectation of Lara Sullivan's long-term commitment and contribution to Pyxis Oncology's future operations and strategic direction.

Management Comments

• "Lara Sullivan, M.D. is the President, Chief Executive Officer and Chief Medical Officer of Pyxis Oncology, Inc."
• "In connection with Lara Sullivan's role as President, Chief Executive Officer and Chief Medical Officer of the Issuer, on March 31, 2025, the Issuer granted the Reporting Person a stock option to purchase 918,308 Shares at an exercise price of $0.98 per share."
• "Such stock options vest over a four year period, with 25% vesting on the first anniversary of the grant date, and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued employment through the applicable vesting date."

Industry Context

This filing is a routine disclosure of executive beneficial ownership and compensation, common in the biotechnology industry where stock-based incentives are a primary component of executive remuneration to align interests with long-term company performance and shareholder value.

Comparison to Industry Standards

• The structure of the stock option grant, including the exercise price and four-year vesting schedule, aligns with common executive compensation practices in the biotechnology industry, which heavily rely on equity incentives to align management interests with long-term shareholder value. However, the document does not provide specific comparable companies or projects to benchmark the grant size or terms against.

Related Party Transactions

• The stock option grant to Lara Sullivan, as President, CEO, and Chief Medical Officer, is a transaction between the Issuer and a key executive, which is a common form of related party compensation.

Stakeholder Impact

• Shareholders: Increased alignment of CEO's interests with shareholder value through equity incentives. Potential dilution from future option exercises, though this is standard.
• Employees: No direct impact mentioned, but a stable leadership team can positively influence employee morale and strategic direction.
• Management: Lara Sullivan's compensation structure is clearly defined, incentivizing her continued performance and tenure.

Next Steps

• Continued employment of Lara Sullivan to ensure vesting of stock options and RSUs.
• Future disclosures of beneficial ownership changes as required by SEC regulations.

Key Dates

Recommendation

Keywords

Pyxis Oncology, Lara Sullivan, Schedule 13D, Beneficial Ownership, Stock Options, RSUs, Executive Compensation, Biotechnology, SEC Filing, PYXS